Pfizer (PFE) Cash from Financing Activities (2009 - 2026)

Pfizer (PFE) has 18 years of Cash from Financing Activities data on file, last reported at -$2.9 billion in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$2.9 billion, up 45.36% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.9 billion (up 67.81% YoY), and the FY2025 annual result was -$10.3 billion, up 39.88% from the prior year.
• Cash from Financing Activities retreated to -$2.9 billion in Q1 2026 per PFE's latest filing, from $596.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $27.2 billion in Q3 2023 and troughed at -$12.0 billion in Q3 2024.
• A 5-year average of -$1.4 billion and a median of -$2.9 billion in 2026 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities soared 978.33% in 2023, then sank 218.23% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at -$9.8 billion in 2022, then jumped by 155.42% to $5.4 billion in 2023, then sank by 320.98% to -$12.0 billion in 2024, then soared by 104.96% to $596.0 million in 2025, then plunged by 579.19% to -$2.9 billion in 2026.
• Business Quant data shows PFE's Cash from Financing Activities at -$2.9 billion in Q1 2026, $596.0 million in Q4 2025, and -$2.5 billion in Q3 2025.